Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Summary

Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings. In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction. The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.

Eligibility

Inclusion Criteria:

* Adult patient (≥18 years old)
* Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024
* At least 3 biological signs of HLH:

  * ferritin \> 2000 ng/mL
  * triglycerides \> 1.5 g/L
  * at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL).

Exclusion Criteria:

Refusal to participate in the study

Conditions3

Browse More Trials